Bradley Merrill Thompson, Member of the Firm, will speak at CGMPs for Combination Products - Final Rule and Implementation, hosted by the Regulatory Affairs Professionals Society (RAPS).

On 22 January 2013, the US Food and Drug Administration (FDA) issued the final rule on current Good Manufacturing Practices (CGMPs) for combination products. This highly anticipated rule is intended to clarify how the agency's GMP requirements apply to the manufacturing operations of combination products companies. While the final rule did not change significantly from the proposed rule, the agency indicated that many of the existing ambiguities will be clarified through guidance documents.

Offered in collaboration with the Combination Products Coalition (CPC), this program offers the unique opportunity to examine the contents of the final rule and the agency's implementation plan with representatives from FDA's Office of Combination Products and industry peers. You will hear directly from experts at each of the FDA centers and industry regarding what the final rule includes, with an emphasis on deviations from the proposed rule, as well as how the final rule may affect you and your company.

Working intensively in small groups facilitated by experts from CPC, you will use a case study approach to apply the final rule and analyze the rule's remaining ambiguities and identify approaches for effective implementation. You will then benefit from a final recap session during which the expert facilitators will present and connect major themes identified during the breakouts, allowing for organic discussions and problem solving by the group as a whole. Additionally, you will have the opportunity to provide feedback directly to the experts at the various centers responsible for developing the implementation guidance regarding any other ambiguities not addressed in the case studies. 

As well as the opportunity to provide feedback directly to FDA experts during the program, RAPS and CPC will collaborate to compile the major themes that emerge from the program regarding implementation and submit them as comments that FDA will consider when developing its guidelines for implementation. Don't miss your opportunity to provide your input on this pivotal issue.

For more information, visit

Event Detail

Regulatory Affairs Professionals Society (RAPS)
Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.